

I. AMENDMENTS

IN THE CLAIMS

Cancel claims 4, 9-19, 21-32, and 34-62 without prejudice to renewal.

Please enter the amendments to claims 1, 2, 20, 33, and 63, as shown below.

1. (Currently Amended) A method for attracting a ~~glial~~ neural and glial progenitor cell, or a progeny of a ~~glial~~ neural progenitor cell, to a site of damage or lesion in a central nervous system (CNS) tissue, the method comprising

parenterally administering to an individual having CNS damage or lesion a sufficient amount of a TGF- α polypeptide or a functional fragment thereof ~~compound that binds to an epidermal growth factor (EGF)/ ErbB family receptor~~, wherein said administration is outside of the ventricles, and wherein said administering effects migration of the glial neural progenitor cell or progeny thereof ~~is attracted to~~ the site of damage or lesion in the CNS ~~central nervous system (CNS)~~ tissue.

2. (Currently Amended) The method of claim 1, further comprising administering a sufficient amount of the compound to stimulate differentiation of the ~~glial~~ neural progenitor cell or progeny thereof.

3. (Original) The method of claim 1, wherein the compound is administered *in vivo*.

4. (Canceled)

5. (Original) The method of claim 1, wherein the compound is administered by intrastriatal infusion.

6. (Original) The method of claim 1, wherein the central nervous system (CNS) tissue is brain tissue.

7. (Original) The method of claim 6, wherein the brain tissue is adjacent to a subependymal zone.

8. (Original) The method of claim 1, wherein the central nervous system (CNS) tissue is spinal cord tissue and spinal nerve root origins.

9.-19. (Canceled)

20. (Currently Amended) The method of claim 1, wherein the CNS tissue is in tissue culture, and wherein the compound is administered to the tissue culture comprising a ~~glial~~ neural progenitor cell.

21.-32. (Canceled)

33. (Currently Amended) A method for attracting a ~~glial~~ neural progenitor cell, or a progeny thereof, to a site of damage or lesion in a central nervous system (CNS) tissue, the method comprising administering a sufficient amount of transforming growth factor alpha (TGF α) polypeptide, or functional fragment thereof, to the site to attract the ~~glial~~ neural progenitor cell or its progeny to the site, wherein said administration is outside of the ventricles.

34.-62. (Canceled)

63. (Currently Amended) A method for attracting a ~~glial~~ neural progenitor cell, or a progeny thereof, to a site of damage or lesion in a central nervous system (CNS) tissue, the method comprising ^{intra}intrastriatal administering ^{contd} a sufficient amount of transforming growth factor alpha (TGF α) polypeptide, or functional fragment thereof, to the site to attract the ~~glial~~ neural progenitor cell or its progeny to the site.

64. (Previously Added) The method of claim 33, wherein said administration is by continuous infusion.